Opsidio has initiated dosing of the initial participant in a Phase 2a study evaluating OpSCF for the treatment of moderate to severe eczema.

ASC Therapeutics has reported the inaugural administration to a patient in their Phase I/IIa study for their prime drug, ASC618, conducted at Arkansas Children's Hospital.

Longboard Pharmaceuticals, Inc., a company focused on developing new treatments for neurological conditions, has announced the start of a Phase 1 trial. This randomized, double-blind, placebo-controlled study will assess their drug candidate, LP659, in a Single Ascending Dose (SAD) format.

OliX Pharmaceuticals has disclosed encouraging initial safety outcomes and signs of effectiveness from a Phase 1 study evaluating OLX10212 for treating age-related macular degeneration.

Arrowhead Pharmaceuticals has submitted an application to begin an early-stage clinical trial, evaluating ARO-DM1 in patients with Myotonic Dystrophy Type 1.

Internationally recognized biotech company CSL, in partnership with Arcturus Therapeutics, has made public that the Ministry of Health, Labor and Welfare in Japan has officially sanctioned the use of ARCT-154.

Rallybio Reveals Initial Multi-Dose Results from Finalized Phase 1 Evaluation on Safety and Drug Dynamics for RLYB212, a Monoclonal Antibody Targeting HPA-1a to Avert Thrombocytopenia in Infants and Newborns.

Tectonic Therapeutics, known for GPCR-targeted therapies, has successfully dosed the first cohort in human trials for its Fc-relaxin RXFP1 receptor project.

Escient Pharmaceuticals Commences First Human Study for EP262, a Novel Oral Drug Blocking MRGPRX2, Aimed at Treating Eczema.

TOLREMO Initiates Phase 1 Study by Administering TT125-802 to Initial Participant, an Innovative Compound Targeting Transcriptional Resistance in Cancer Treatment.

Aldeyra Therapeutics, Inc. has disclosed that it has received a Complete Response Letter from the FDA regarding the New Drug Application of reproxalap.

NMRA-266, a molecule with selective affinity for enhancing the activity of the M4 muscarinic receptor, is being advanced by Neumora as a potential therapeutic option for the management of schizophrenia as well as various additional mental health conditions.